Cardiac surgery for children with trisomies 13 and 18: Where are we now?

Annie Janvier1, Barbara Farlow2, Keith Barrington3

  • 1Department of Pediatrics, University of Montreal, Montreal, Canada; Unité d'éthique clinique, Hôpital Sainte-Justine, Quebec, Canada; Research Center, Hôpital Sainte-Justine, Quebec, Canada.

Seminars in Perinatology
|February 6, 2016
PubMed

Insights

Cardiac surgery for trisomy 13 or 18 (T13/18) requires individualized assessment. While potentially beneficial for some, it may harm others, necessitating careful consideration of family goals and patient health.

Area of Science:

  • Pediatric Cardiology
  • Clinical Genetics
  • Congenital Heart Disease

Background:

  • Trisomy 13 and trisomy 18 (T13/18) were historically considered "lethal" conditions.
  • Recent research highlights the heterogeneity of T13/18, with increasing interventions reported.
  • Interpreting outcomes of cardiac surgery in T13/18 is complex due to practice variations and study limitations.

Purpose of the Study:

  • To evaluate the potential benefits and risks of cardiac surgery for children with T13/18.
  • To explore individualized approaches for surgical decision-making in T13/18.
  • To examine communication strategies with families regarding surgical options.

Main Methods:

  • Case study analysis of two children with T13/18 in different clinical scenarios.
  • Review of existing literature on cardiac surgery outcomes in T13/18.
  • Discussion of factors influencing surgical candidacy and outcomes.

Main Results:

  • Cardiac surgery may offer benefits to select children with T13/18.
  • Potential for harm exists, underscoring the need for careful patient selection.
  • Older, healthier children without respiratory support may be more likely to benefit.

Conclusions:

  • Individualized assessment is crucial for determining the appropriateness of cardiac surgery in T13/18.
  • Family-centered goals must guide surgical decisions.
  • Further rigorous research is needed to identify predictors of survival and benefit in T13/18.

Related Concept Videos

Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
422
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
671
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
621